NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PhotoPharmics

PhotoPharmics

Private
Lehi, UtahHealthcare & Life Scienceshttps://photopharmics.com/

Last Round

Series B

Extension

Apr 18, 2025

Total Funding Raised

$22.64M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PhotoPharmics is a clinical-stage medical device company developing next-generation photo-neuromodulation therapies for neurodegenerative disorders, with an initial focus on Parkinson's disease.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

medical devicelight therapylight therapy devicephotobiomodulationParkinson's diseaseneuromodulationhome-use medical devicenon-invasive treatmentmovement disorder treatmentneurodegenerative diseasered light therapyclinical trialsFDA breakthrough designationdigital healthbiohacking

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PhotoPharmics Comparables

Compare PhotoPharmics with similar companies based on industry and business-model similarity.

PhotoPharmics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gondola Medical Technologies
79%
Cala Health
79%
Vielight Inc.
78%

PhotoPharmics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionApr 18, 2025
Series BNov 15, 2023
GrantSep 24, 2021
Series BApr 29, 2020

PhotoPharmics Investors

Notable investors and investment history

PhotoPharmics investors
InvestorRounds
Frazier GroupSeries B
Vectra Management GroupSeries B
NIH RADxGrant
KickstartSeries B Extension, Series B
Angel Star VenturesSeries B
Frazier VCConvertible Debt, Seed
National Institute on Drug AbuseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Monthly visitors increased 36% MoM.

  • Apr 18, 2025

    $6M round led by Kickstart.

PhotoPharmics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PhotoPharmics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PhotoPharmics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLehi, Utah
Employee Range9
Year Founded2011
Last FundingApr 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.